Sign In
Buy CYCC
$6.37
+0 (+0%)
At Close: Dec 10, 2025
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
09:15am, Tuesday, 20'th Feb 2024
BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
09:15am, Tuesday, 30'th Jan 2024
BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
Why Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today?
09:07am, Tuesday, 09'th Jan 2024
Cyclacel Pharmaceuticals (NASDAQ: CYCC ) stock is falling on Tuesday but it's not due to any negative news from the clinical-stage biopharmaceutical company. Instead, shares of CYCC stock are retreat
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
09:15am, Monday, 08'th Jan 2024
BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
09:15am, Tuesday, 02'nd Jan 2024
BERKELEY HEIGHTS, N.J., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
09:15am, Friday, 22'nd Dec 2023
BERKELEY HEIGHTS, N.J., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
- Patient Pharmacodynamic Data Show Decrease in CDKN2A, CDKN2B, and PRMT5 Protein Levels - - A Squamous Non-Small Cell Lung Cancer Patient with CDKN2B Deletion Achieved Marked Tumor Shrinkage after On
Cyclacel Pharmaceuticals Announces Reverse Stock Split
04:05pm, Tuesday, 12'th Dec 2023
BERKELEY HEIGHTS, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
09:15am, Thursday, 30'th Nov 2023
BERKELEY HEIGHTS, N.J., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results
09:15am, Tuesday, 07'th Nov 2023
BERKELEY HEIGHTS, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
New Strong Buy Stocks for October 17th
08:16am, Tuesday, 17'th Oct 2023
MNTX, PGNY, GFF, RKDA and CYCC have been added to the Zacks Rank #1 (Strong Buy) List on October 17, 2023.
Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
09:15am, Thursday, 03'rd Aug 2023
BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
Cyclacel Pharmaceuticals Inc. (CYCC) Q1 2023 Earnings Call Transcript
07:59pm, Thursday, 11'th May 2023
Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - CEO Mark Kirschbaum - CMO Paul McBarron - CFO
Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results
09:15am, Thursday, 04'th May 2023
BERKELEY HEIGHTS, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me
Cyclacel Pharmaceuticals to Participate in March Investor Conferences
09:15am, Tuesday, 07'th Mar 2023
BERKELEY HEIGHTS, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative
